Literature DB >> 30885653

Outcomes and clinical implications of intranasal insulin administration to the central nervous system.

João C P Santiago1, Manfred Hallschmid2.   

Abstract

Insulin signaling in the brain plays a critical role in metabolic control and cognitive function. Targeting insulinergic pathways in the central nervous system via peripheral insulin administration is feasible, but associated with systemic effects that necessitate tight supervision or countermeasures. The intranasal route of insulin administration, which largely bypasses the circulation and thereby greatly reduces these obstacles, has now been repeatedly tested in proof-of-concept studies in humans as well as animals. It is routinely used in experimental settings to investigate the impact on eating behavior, peripheral metabolism, memory function and brain activation of acute or long-term enhancements in central nervous system insulin signaling. Epidemiological and experimental evidence linking deteriorations in metabolic control such as diabetes with neurodegenerative diseases imply pathophysiological relevance of dysfunctional brain insulin signaling or brain insulin resistance, and suggest that targeting insulin in the brain holds some promise as a therapy or adjunct therapy. This short narrative review gives an overview over recent findings on brain insulin signaling as derived from human studies deploying intranasal insulin, and evaluates the potential of therapeutic interventions that target brain insulin resistance.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Central nervous system insulin signaling; Cognitive function; Diabetes; Intranasal insulin; Memory; Metabolic control; Obesity

Mesh:

Substances:

Year:  2019        PMID: 30885653     DOI: 10.1016/j.expneurol.2019.03.007

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  11 in total

Review 1.  Imaging of intranasal drug delivery to the brain.

Authors:  Michael C Veronesi; Mosa Alhamami; Shelby B Miedema; Yeonhee Yun; Miguel Ruiz-Cardozo; Michael W Vannier
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-02-25

Review 2.  Neuroendocrine microRNAs linked to energy homeostasis: future therapeutic potential.

Authors:  Kimberly W Y Mak; Aws F Mustafa; Denise D Belsham
Journal:  Pharmacol Rep       Date:  2022-09-09       Impact factor: 3.919

Review 3.  Regulation of Metabolic Health by an "Olfactory-Hypothalamic Axis" and Its Possible Implications for the Development of Therapeutic Approaches for Obesity and T2D.

Authors:  Mara Alaide Guzmán-Ruiz; Adriana Jiménez; Alfredo Cárdenas-Rivera; Natalí N Guerrero-Vargas; Diana Organista-Juárez; Rosalinda Guevara-Guzmán
Journal:  Cell Mol Neurobiol       Date:  2021-04-04       Impact factor: 5.046

Review 4.  New Opportunity to Formulate Intranasal Vaccines and Drug Delivery Systems Based on Chitosan.

Authors:  Roxana Popescu; Mihaela Violeta Ghica; Cristina-Elena Dinu-Pîrvu; Valentina Anuța; Dumitru Lupuliasa; Lăcrămioara Popa
Journal:  Int J Mol Sci       Date:  2020-07-16       Impact factor: 5.923

Review 5.  Brain Insulin Resistance and Hippocampal Plasticity: Mechanisms and Biomarkers of Cognitive Decline.

Authors:  Matteo Spinelli; Salvatore Fusco; Claudio Grassi
Journal:  Front Neurosci       Date:  2019-07-31       Impact factor: 4.677

Review 6.  Obesity: sex and sympathetics.

Authors:  Zhigang Shi; Jennifer Wong; Virginia L Brooks
Journal:  Biol Sex Differ       Date:  2020-03-11       Impact factor: 5.027

7.  Lack of insulin resistance in response to streptozotocin treatment in neuronal SH-SY5Y cell line.

Authors:  Fruzsina Bagaméry; Kamilla Varga; Kitti Kecsmár; István Vincze; Éva Szökő; Tamás Tábi
Journal:  J Neural Transm (Vienna)       Date:  2019-12-19       Impact factor: 3.575

8.  Revealing the Modular Similarities and Differences Among Alzheimer's Disease, Vascular Dementia, and Parkinson's Disease in Genomic Networks.

Authors:  Yafei Chen; Qiong Liu; Jun Liu; Penglu Wei; Bing Li; Nongyun Wang; Zhenquan Liu; Zhong Wang
Journal:  Neuromolecular Med       Date:  2021-06-12       Impact factor: 3.843

9.  Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes.

Authors:  Carmen Hierro-Bujalance; Carmen Infante-Garcia; Angel Del Marco; Marta Herrera; Maria Jose Carranza-Naval; Javier Suarez; Pilar Alves-Martinez; Simon Lubian-Lopez; Monica Garcia-Alloza
Journal:  Alzheimers Res Ther       Date:  2020-04-07       Impact factor: 6.982

10.  The Impact of Differentiation on Cytotoxicity and Insulin Sensitivity in Streptozotocin Treated SH-SY5Y Cells.

Authors:  Fruzsina Bagaméry; Kamilla Varga; Kitti Kecsmár; István Vincze; Éva Szökő; Tamás Tábi
Journal:  Neurochem Res       Date:  2021-02-22       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.